A multicenter randomized phase II study of second line chemotherapy with epirubicin (Farmorubicin) versus the pegylated liposomal doxorubicin [Caelyx] in advanced breast cancer patients.
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2013
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Epirubicin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Feb 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 26 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 26 Jun 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.